As a family-run business, our sense of togetherness and fair and cooperative interaction are the cornerstones of our corporate culture. We have flat hierarchies and short decision-making paths. The right environment for ideas and impulses.
If you take a look at the German economy, and in particular at medium-sized companies, you will see that more than 90 percent of them are family-owned. These types of companies place a high value on sustainable management and reinvest their profits in the further development of their business and the recruitment and development of their employees. Plasmatreat works exactly in the same way: We invest over 12% of our turnover each year in funding our extensive research and development department and hold over 150 patents on plasma systems and processes. In this way, we secure our technological leadership and the jobs and futures of our employees.
Our CEO's Christian, Lukas and Magnus Buske care deeply about their company and its employees around the world. With prudence and foresight, Christian Buske introduced his four sons to Plasmatreat and its technology at an early age. They got to know the company and the technology in various summer jobs and internships.
Two of the sons, Magnus and Lukas Buske, showed an early interest in the special and sustainable technology for surface treatment and oriented their professional careers towards joining the family business. They studied mechanical or industrial engineering and, after working for other companies such as Audi AG or Jowat Klebstoffe, joined the company as team leaders in various positions.
After several years as team leaders, Magnus Buske was appointed Global Leader for Research & Development and Lukas Buske Head of Plasma Applications in 2019. Following the expansion of the management team to include Lukas and Magnus Buske in autumn 2022, the two sons have been entered in the commercial register since the beginning of 2024 and are thus officially managing directors of Plasmatreat GmbH.
With the commitment of the two sons, the future of Plasmatreat remains in family hands and another building block is being laid.